Get started
Author

Albrecht Stenzinger

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
2010 · A. Kasajima, M. Pavel, et al. · Endocrine Related Cancer · 104
PDF
Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
2025 · C. Kropf-Sanchen, A. Rasokat, et al. · ESMO Open · 8
PDF
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium
2025 · S.F. Haj Mohammad, H. van der Pol, et al. · ESMO Open · 6
Mismatch repair deficiency and microsatellite instability in adrenocortical carcinoma
2026 · B. Altieri, S. Kircher, et al. · ESMO Open · 5
PDF
572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer
2022 · W. Weichert, S. Bartels, et al. · Annals of Oncology · 4
PDF
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
2024 · J. García-Foncillas, D. Arnold, et al. · Annals of Oncology · 2
PDF
1442P DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC)
2023 · J.B. Kuon, M. Blasi, et al. · Annals of Oncology · 1
PDF
1021P DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints
2022 · J.B. Kuon, M. Blasi, et al. · Annals of Oncology · 1
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology
2026 · A. El Helali, C. Cardone, et al. · Annals of Oncology
Assessing clinical decision support system tools in precision oncology: piloting ring testing
2026 · V. Nygaard, S. Zhao, et al. · ESMO Real World Data and Digital Oncology
PDF
525P Predictive value of the molecular landscape & genetic heterogeneity in response to neoadjuvant treatment in esophagogastric adenocarcinoma: The NCT OPPOSITE trial
2026 · S. Schlue, S.S. Mughal, et al. · Annals of Oncology
PDF
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations
2026 · Cornelia Kropf-Sanchen, Nikolaj Frost, et al. · Clinical Lung Cancer
438P Chemoimmunotherapy versus chemotherapy for extensive-stage small cell lung cancer: A retrospective real-world study of 904 patients
2026 · K. Dimitriou, S. Shi, et al. · ESMO Open
PDF
62P Clinical and molecular characteristics of NRAS mutations in advanced non-small cell lung cancer (NSCLC)
2026 · J. Anselm, A. Rasokat, et al. · ESMO Open
340P European thoracic oncology platform lungscope project: Matched primary NSCLC and metastases
2026 · J. Naidoo, U. Dafni, et al. · ESMO Open
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
2026 · Markus Ball, Susanne Beck, et al. · British Journal of Cancer
PDF
Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite‐unstable gastrointestinal cancers: A pilot study
2026 · Aysel Ahadova, Lena Bohaumilitzky, et al. · International Journal of Cancer
PDF
Prognostic impact of spatial niches in prostate cancer
2026 · Felix Schneider, Sarah Heike Böning, et al. · Scientific Reports
PDF
45P Prospective immunophenotyping to predict clinical outcomes in small cell lung cancer
2025 · S. Shi, M. Blasi, et al. · Immuno-Oncology Technology
P3.12.61 Retrospective Multicenter Study Within the German Network Genomic Medicine Lung Cancer on RET Fusions as Resistance in EGFR-Mutant Lung Cancer
2025 · C. Kropf-Sanchen, N. Frost, et al. · Journal of Thoracic Oncology
155eP Microcosting analysis of combined whole genome sequencing and whole transcriptome sequencing in cancer diagnostics
2025 · C. Altbürger, D. Kazdal, et al. · ESMO Open
PDF
2251P Immune features of the tumor microenvironment are mirrored in PBMCs and predict second-line outcome in advanced pancreatic cancer: Insights from the PREDICT trial
2025 · A. Lahusen, M.P. Lutz, et al. · Annals of Oncology
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome—a case for universal genetic testing?
2025 · D. William, M. Bermúdez, et al. · ESMO Gastrointestinal Oncology
PDF
185P Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
2024 · M. Pouyiourou, G. Zaun, et al. · Annals of Oncology
PDF
1450P Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
2024 · G.M. Haag, T.O. Goetze, et al. · Annals of Oncology
PDF
Works count: 30
Citation count: 131
H-index: 4
I10-index: 1
Year
Topic
Type